Sara Lodi

Sara Lodi, PhD

Associate Professor, Biostatistics - Boston University School of Public Health


Sara Lodi is an Associate Professor of Biostatistics at the Boston University School of Public Heath. She obtained her PhD in Medical Statistics at the London School of Hygiene and Tropical Medicine in 2009, UK. Her research focuses on causal inference methods for observational studies using big data, methods for causal inference to improve the statistical analysis of clinical trials, and the reconciliation of results from clinical trials and observational studies. She leads cutting edge research that focuses on the translation of methodologic advancements in causal inference into actionable findings for real world public health research questions, mainly in the areas of infectious diseases (HIV, hepatitis C, tuberculosis) and substance use disorder. She has published many articles on behalf of large international collaborations of HIV cohorts such as CASCADE, COHERE and the HIV-CAUSAL, and HepCAUSAL collaborations. She’s been an instructor for both BS851 Applied Statistics in Clinical Trials and BS807 Applied Causal Inference in Health Research.


  • London School of Hygiene & Tropical Medicine, PhD Field of Study: Statistics
  • University of Southampton, MSc Field of Study: Statistics
  • Univ of Bologna, BA Field of Study: Statistics


  • Published on 9/12/2023

    Hansford HJ, Cashin AG, Jones MD, Swanson SA, Islam N, Dahabreh IJ, Dickerman BA, Egger M, Garcia-Albeniz X, Golub RM, Lodi S, Moreno-Betancur M, Pearson SA, Schneeweiss S, Sterne J, Sharp MK, Stuart EA, Hernan MA, Lee H, McAuley JH. Development of the TrAnsparent ReportinG of observational studies Emulating a Target trial (TARGET) guideline. BMJ Open. 2023 Sep 12; 13(9):e074626. PMID: 37699620.

    Read At: PubMed
  • Published on 9/5/2023

    Hansford HJ, Cashin AG, Jones MD, Swanson SA, Islam N, Douglas SRG, Rizzo RRN, Devonshire JJ, Williams SA, Dahabreh IJ, Dickerman BA, Egger M, Garcia-Albeniz X, Golub RM, Lodi S, Moreno-Betancur M, Pearson SA, Schneeweiss S, Sterne JAC, Sharp MK, Stuart EA, Hernán MA, Lee H, McAuley JH. Reporting of Observational Studies Explicitly Aiming to Emulate Randomized Trials: A Systematic Review. JAMA Netw Open. 2023 Sep 05; 6(9):e2336023. PMID: 37755828.

    Read At: PubMed
  • Published on 4/28/2023

    Rodriguez CA, Lodi S, Horsburgh CR, Mitnick CD, Bastard M, Huerga H, Khan U, Rich M, Seung KJ, Atwood S, Manzur-Ul-Alam M, Melikyan N, Mpinda S, Myint Z, Naidoo Y, Petrosyan O, Salahuddin N, Sarfaraz S, Vilbrun SC, Yae K, Achar J, Ahmed S, Algozhina E, Beauchamp J, de Guadelupe Perea Moreno S, Gulanbaeva M, Gergedava M, Indah Sari CY, Hewison C, Khan P, Franke MF. Comparative effectiveness of adding delamanid to a multidrug-resistant tuberculosis regimen comprised of three drugs likely to be effective. PLOS Glob Public Health. 2023; 3(4):e0000818. PMID: 37115740.

    Read At: PubMed
  • Published on 4/19/2023

    Sewak A, Lodi S, Li X, Shu D, Wen L, Mayer KH, Krakower DS, Young JG, Marcus JL. Causal effects of stochastic PrEP interventions on HIV incidence among men who have sex with men. Am J Epidemiol. 2023 Apr 19. PMID: 37073419.

    Read At: PubMed
  • Published on 3/31/2023

    Beesiga B, Marson K, Fatch R, Emenyonu NI, Adong J, Kekibiina A, Puryear S, Lodi S, McDonell MG, Muyindike WR, Kamya MR, Hahn JA, Chamie G. Effects of a COVID-19 Public Health Lockdown on Drinking and Health Behavior Among Persons with HIV and with Unhealthy Alcohol use in Uganda. AIDS Behav. 2023 Oct; 27(10):3213-3222. PMID: 37000383.

    Read At: PubMed
  • Published on 3/20/2023

    Luoma JB, Rossi SL, Sereda Y, Pavlov N, Toussova O, Vetrova M, Bendiks S, Kiriazova T, Krupitsky E, Lioznov D, Blokhina E, Lodi S, Lunze K. An acceptance-based, intersectional stigma coping intervention for people with HIV who inject drugs-a randomized clinical trial. Lancet Reg Health Eur. 2023 May; 28:100611. PMID: 37180745.

    Read At: PubMed
  • Published on 2/13/2023

    van Santen DK, Lodi S, Dietze P, van den Boom W, Hayashi K, Dong H, Cui Z, Maher L, Hickman M, Boyd A, Prins M. Comprehensive needle and syringe program and opioid agonist therapy reduce HIV and hepatitis c virus acquisition among people who inject drugs in different settings: A pooled analysis of emulated trials. Addiction. 2023 Jun; 118(6):1116-1126. PMID: 36710474.

    Read At: PubMed
  • Published on 12/1/2022

    Lodi S, Klein M, Rauch A, Epstein R, Wittkop L, Logan R, Rentsch CT, Justice AC, Touloumi G, Berenguer J, Jarrin I, Egger M, Puoti M, D'Arminio Monforte A, Gill J, Salmon Ceron D, van Sighem A, Linas B, van der Valk M, Hernán MA. Sustained virological response after treatment with direct antiviral agents in individuals with HIV and hepatitis C co-infection. J Int AIDS Soc. 2022 Dec; 25(12):e26048. PMID: 36562643.

    Read At: PubMed
  • Published on 11/11/2022

    Turcinovic J, Schaeffer B, Taylor BP, Bouton TC, Odom-Mabey AR, Weber SE, Lodi S, Ragan EJ, Connor JH, Jacobson KR, Hanage WP. Understanding Early Pandemic Severe Acute Respiratory Syndrome Coronavirus 2 Transmission in a Medical Center by Incorporating Public Sequencing Databases to Mitigate Bias. J Infect Dis. 2022 Nov 11; 226(10):1704-1711. PMID: 35993116.

    Read At: PubMed
  • Published on 11/10/2022

    Rodriguez CA, Lodi S, Horsburgh CR, Bastard M, Hewison C, Huerga H, Khan M, Khan PY, Khan U, Oyewusi L, Padayachee S, Mitnick CD, Franke MF. Selection bias in multidrug-resistant tuberculosis cohort studies assessing sputum culture conversion. PLoS One. 2022; 17(11):e0276457. PMID: 36355658.

    Read At: PubMed

News & In the Media